{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T10:10:55Z","timestamp":1683108655130},"reference-count":60,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.vaccine.2005.05.005","type":"journal-article","created":{"date-parts":[[2005,6,5]],"date-time":"2005-06-05T11:14:55Z","timestamp":1117970095000},"page":"4821-4833","source":"Crossref","is-referenced-by-count":11,"title":["Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines"],"prefix":"10.1016","volume":"23","author":[{"given":"Maija","family":"Toropainen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Wedege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Bolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Helena","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"K\u00e4yhty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2005.05.005_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib2","first-page":"667","article-title":"A controlled field trial of a serogroup A meningococcal polysaccharide vaccine","volume":"48","author":"Wahdan","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"9251","key":"10.1016\/j.vaccine.2005.05.005_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(00)03594-7","article-title":"Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England","volume":"357","author":"Ramsay","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2005.05.005_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"issue":"8346","key":"10.1016\/j.vaccine.2005.05.005_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2005.05.005_bib6","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib7","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib8","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"issue":"10","key":"10.1016\/j.vaccine.2005.05.005_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0264-410X(96)00001-1","article-title":"Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine","volume":"14","author":"Peeters","year":"1996","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2005.05.005_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/mpat.1995.0038","article-title":"The Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis and reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes","volume":"18","author":"Muttilainen","year":"1995","journal-title":"Microb Pathog"},{"issue":"7","key":"10.1016\/j.vaccine.2005.05.005_bib12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1084\/jem.185.7.1173","article-title":"Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection","volume":"185","author":"Martin","year":"1997","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/IAI.69.3.1561-1567.2001","article-title":"Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection","volume":"69","author":"West","year":"2001","journal-title":"Infect Immun"},{"issue":"5459","key":"10.1016\/j.vaccine.2005.05.005_bib14","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"8775","key":"10.1016\/j.vaccine.2005.05.005_bib15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"8827","key":"10.1016\/j.vaccine.2005.05.005_bib16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib17","first-page":"147","article-title":"Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey","volume":"14","author":"H\u00f8iby","year":"1991","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib18","first-page":"169","article-title":"Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies","volume":"14","author":"Rosenqvist","year":"1991","journal-title":"NIPH Ann"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib19","first-page":"183","article-title":"Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial","volume":"14","author":"Wedege","year":"1991","journal-title":"NIPH Ann"},{"issue":"10","key":"10.1016\/j.vaccine.2005.05.005_bib20","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1128\/IAI.66.10.4755-4761.1998","article-title":"Specificity of bactericidal antibody response to serogroup B meningococcal strains in brazilian children after immunization with an outer membrane vaccine","volume":"66","author":"Milagres","year":"1998","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2005.05.005_bib21","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1128\/IAI.66.7.3223-3231.1998","article-title":"Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial","volume":"66","author":"Wedege","year":"1998","journal-title":"Infect Immun"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2005.05.005_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2005.05.005_bib24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2005.05.005_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1699-0463.1991.tb01258.x","article-title":"Immunization against serogroup B meningococci. Opsonin response in vaccinees as measured by chemiluminescence","volume":"99","author":"Lehmann","year":"1991","journal-title":"APMIS"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/infdis\/167.6.1314","article-title":"Cross-reacting serum opsonins to meningococci after vaccination","volume":"167","author":"Guttormsen","year":"1993","journal-title":"J Infect Dis"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2005.05.005_bib27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0264-410X(98)00259-X","article-title":"Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine","volume":"17","author":"Naess","year":"1999","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2005.05.005_bib28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1046\/j.1365-3083.1998.00319.x","article-title":"Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine","volume":"47","author":"Aase","year":"1998","journal-title":"Scand J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2005.05.005_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/00006454-200111000-00010","article-title":"Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants","volume":"20","author":"Morley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/IAI.66.3.959-965.1998","article-title":"Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine","volume":"66","author":"Naess","year":"1998","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2005.05.005_bib31","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1128\/IAI.69.7.4502-4508.2001","article-title":"Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine","volume":"69","author":"Perez","year":"2001","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2005.05.005_bib32","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1128\/IAI.71.7.3775-3781.2003","article-title":"Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine","volume":"71","author":"Wedege","year":"2003","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2005.05.005_bib33","first-page":"41","article-title":"The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates","volume":"28","author":"Sifontes","year":"1997","journal-title":"Arch Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2005.05.005_bib34","first-page":"455","article-title":"Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B","volume":"25","author":"Infante","year":"1994","journal-title":"Arch Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2005.05.005_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0882-4010(87)90059-3","article-title":"Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development","volume":"3","author":"Saukkonen","year":"1987","journal-title":"Microb Pathog"},{"issue":"16","key":"10.1016\/j.vaccine.2005.05.005_bib36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0264-410X(95)00101-6","article-title":"The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis","volume":"13","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1995","journal-title":"Vaccine"},{"issue":"20\u201321","key":"10.1016\/j.vaccine.2005.05.005_bib37","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/S0264-410X(99)00049-3","article-title":"The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci","volume":"17","author":"Toropainen","year":"1999","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2005.05.005_bib38","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.63.12.4642-4652.1995","article-title":"Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine","volume":"63","author":"Rosenqvist","year":"1995","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib39","first-page":"99","article-title":"Validation of an ELISA for the measurement of human IgG against serogroup B Neisseria meningitidis protein","volume":"51","author":"Ferriol Marchena","year":"1999","journal-title":"Rev Cubana Med Trop"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0882-4010(88)90070-8","article-title":"Experimental meningococcal meningitis in the infant rat","volume":"4","author":"Saukkonen","year":"1988","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2958.1999.01514.x","article-title":"The opcA and (psi) opcB regions in Neisseria: genes, pseudogenes, deletions, insertion elements and DNA islands","volume":"33","author":"Zhu","year":"1999","journal-title":"Mol Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/CDLI.1.6.729-736.1994","article-title":"Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies","volume":"1","author":"Verheul","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/mpat.2000.0419","article-title":"Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model","volume":"30","author":"Toropainen","year":"2001","journal-title":"Microb Pathog"},{"issue":"4","key":"10.1016\/j.vaccine.2005.05.005_bib44","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1073\/pnas.82.4.1194","article-title":"NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci","volume":"82","author":"Frosch","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib45","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1128\/IAI.69.6.3762-3771.2001","article-title":"Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B","volume":"69","author":"Moe","year":"2001","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2005.05.005_bib46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1086\/368360","article-title":"Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia","volume":"187","author":"Plested","year":"2003","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2005.05.005_bib47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/mpat.1993.1085","article-title":"Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model","volume":"15","author":"Mackinnon","year":"1993","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0882-4010(92)90022-G","article-title":"The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis","volume":"13","author":"Jones","year":"1992","journal-title":"Microb Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2005.05.005_bib49","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1128\/IAI.62.12.5290-5295.1994","article-title":"Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity","volume":"62","author":"Moran","year":"1994","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2005.05.005_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s004300050018","article-title":"Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat","volume":"185","author":"Vogel","year":"1996","journal-title":"Med Microbiol Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2005.05.005_bib51","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1128\/IAI.65.11.4436-4444.1997","article-title":"Sialylation of i lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose","volume":"65","author":"Estabrook","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.05.005_bib52","series-title":"Proceedings of the Ninth International Pathogenic Neisseria Conference","first-page":"437","article-title":"Quality control of the Cuban and Norwegian serogroup B vaccines used in the Iceland study","author":"Griffiths","year":"1994"},{"issue":"6","key":"10.1016\/j.vaccine.2005.05.005_bib53","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2005.05.005_bib54","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2005.05.005_bib55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/IAI.40.1.257-264.1983","article-title":"Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide","volume":"40","author":"Zollinger","year":"1983","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2005.05.005_bib56","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/374648","article-title":"Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection","volume":"187","author":"Williams","year":"2003","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2005.05.005_bib57","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/IAI.72.10.5903-5909.2004","article-title":"Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity","volume":"72","author":"Welsch","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.05.005_bib58","doi-asserted-by":"crossref","unstructured":"Toropainen M, Saarinen L, Wedege E, Bolstad K, Michaelsen TE, Aase A, K\u00e4yhty H. Protection by natural human IgM antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement mediated bacterial lysis. Infect Immun. August 2005, in press.","DOI":"10.1128\/IAI.73.8.4694-4703.2005"},{"issue":"10","key":"10.1016\/j.vaccine.2005.05.005_bib59","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2005.05.005_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0168-1656(00)00294-7","article-title":"Candidate Neisseria meningitidis NspA vaccine","volume":"83","author":"Martin","year":"2000","journal-title":"J Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05005207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05005207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T09:34:30Z","timestamp":1683106470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05005207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":60,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0264410X05005207"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.05.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}